Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2008

01-02-2008

Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin

Authors: K. Woods, J. D. Douketis, K. Kathirgamanathan, Q. Yi, M. Crowther

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2008

Login to get access

Excerpt

Background In patients who require warfarin interruption before surgery and have an elevated international normalized ratio (INR) before surgery, low-dose vitamin K may normalize the INR in time for surgery. Patients and methods In a retrospective cohort study, we assessed the efficacy of 1 mg oral vitamin K to normalize the INR for surgery and whether resistance to re-anticoagulation occurs when warfarin is restarted after surgery. We studied a cohort of patients with an INR 1.4–1.9 on the day before surgery who received 1 mg oral vitamin K (vitamin K group), and a comparator group of patients with a normal INR (≤1.3) on the day before surgery who did not receive vitamin K (no vitamin K group). In both patient groups, we determined the proportion of patients with a normalized INR on the day of surgery and compared the mean INR after surgery when warfarin was resumed. Results Of 43 patients in the vitamin K group, the INR was normalized (≤1.3) in 33 patients (76.6%; 95% confidence interval [CI]: 64.1–89.4), and the INR was normal or near-normal (≤1.4) in 39 patients (90.7%; 95% CI: 82.0–99.4) on the day of surgery. The mean (standard deviation) INR in the vitamin K and no vitamin K group 4–8 days after surgery was 1.75 (0.34) and 1.59 (0.36), respectively (P = 0.56). Conclusions In patients requiring interruption of warfarin for surgery, 1 mg oral vitamin K on the day before surgery can normalize the INR by the day of surgery and may not confer resistance to warfarin re-anticoagulation after surgery. …
Metadata
Title
Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin
Authors
K. Woods
J. D. Douketis
K. Kathirgamanathan
Q. Yi
M. Crowther
Publication date
01-02-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0138-1

Other articles of this Issue 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.